Home > Healthcare > Pharmaceuticals > Finished Drug Form > Omega-3 Prescription Drugs Market
Omega-3 Prescription Drugs Market Size
- Report ID: GMI10789
- Published Date: Aug 2024
- Report Format: PDF
Omega-3 Prescription Drugs Market Size
Omega-3 Prescription Drugs Market size was valued at around USD 1.4 billion in 2023 and is estimated to grow at 8.2% CAGR from 2024 to 2032. Omega-3 prescription drugs are pharmaceutical formulations containing highly purified omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), used to treat or manage conditions like cardiovascular diseases, metabolic disorders, and certain inflammatory or neurological conditions.
The rising prevalence of cardiovascular diseases is a significant driving factor for the market. For instance, according to a report from the World Heart Federation (WHF), global deaths from cardiovascular disease (CVD) surged to 20.5 million in 2021. CVD was the leading cause of death worldwide in 2021, with 80% of these deaths occurring in low- and middle-income countries (LMICs). This underscores the growing need for effective treatments, such as omega-3 prescription drugs, to address and manage cardiovascular conditions and improve global health outcomes.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Omega-3 Prescription Drugs Market Size in 2023: | USD 1.4 Billion |
| Forecast Period: | 2024-2032 |
| Forecast Period 2024-2032 CAGR: | 8.2% |
| 2032 Value Projection: | USD 2.8 Billion |
| Historical Data for: | 2021-2023 |
| No. of Pages: | 125 |
| Tables, Charts & Figures: | 214 |
| Segments covered: | Drug Type, Application, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Furthermore, growing awareness of health benefits, advancements in research and development, and a rising geriatric population are key factors driving the market's growth.
Frequently Asked Questions (FAQ) :
Omega-3 Prescription Drugs Market Scope
